Hoi-Shen Radcliffe - Concepedia

Author

Hoi-Shen Radcliffe

Amgen (United States)

Also Known As

H. Radcliffe, H.-S. Radcliffe, Hoi-Shen Radcliffe, Nicolas Pourbaix

Publications

748

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)Amgen (United Kingdom)Russian Cancer Research Center NN Blokhin Friedrich-Alexander-Universität Erlangen-Nürnberg University Hospital of Zurich

About

Hoi-Shen Radcliffe is an author at Amgen (United States) specializing in medicine, surgery, and bone health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	346
2	Orthopaedics	2	2	205
3	Health Sciences	1	1	64
4	Neurology	1	1	64
5	Surgical Oncology	1	1	141

Hoi-Shen Radcliffe

Publications

572

Citations

H-Index

Page 1

	Year	Citations
Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis Nick Freemantle, Cyrus Cooper, Adolfo Díez‐Pérez, Osteoporosis International Bone DiseaseSkeletal TraumaBone HealthOsteoporosis TreatmentsFracture Diagnostics	2012	141
Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB–IVM1a melanoma: a randomized, open-label, phase 2 trial Reinhard Dummer, David Gyorki, John Hyngstrom, Nature Medicine Surgical OncologyMedicineMelanomaSurgeryNeoadjuvant Talimogene Laherparepvec	2021	141
Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab Tony M. Keaveny, Michael R. McClung, Harry K. Genant, Journal of Bone and Mineral Research	2013	112
Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study Kevin J. Harrington, Anthony Kong, Nicolas Mach, Clinical Cancer Research	2020	104
Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with osteoporosis treated with denosumab Harry K. Genant, Cesar Libanati, Klaus Engelke, Bone Freedom StudyOrthopaedic SurgeryOsteoporosisBone DiseaseHip Trabecular	2013	64
432 3-year results of the phase 2 randomized trial for talimogene laherparepvec (T-VEC) neoadjuvant treatment plus surgery vs surgery in patients with resectable stage IIIB-IVM1a melanoma Reinhard Dummer, David Gyorki, John Hyngstrom, Regular and Young Investigator Award Abstracts	2020	10

Page 1